Fabian Meienberg
Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial
Bilz S, Flückiger M, Meienberg F, Falconnier C, Keller U, Puder J. Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial. PloS one 2018; 13:e0202007.
16.08.2018Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial
16.08.2018PloS one 2018; 13:e0202007
Bilz Stefan, Flückiger Miriam, Meienberg Fabian, Falconnier Claudine, Keller Ulrich, Puder Jardena J
Disturbed sphingolipid metabolism with elevated 1-deoxysphingolipids in glycogen storage disease type I - A link to metabolic control
Hornemann T, Baumgartner M, Christ E, Bilz S, Meienberg F, Jung H, Gautschi M, Cremonesi A, Zhakupova A, Hagenbuch N, Alecu I, Hochuli M. Disturbed sphingolipid metabolism with elevated 1-deoxysphingolipids in glycogen storage disease type I - A link to metabolic control. Mol Genet Metab 2018; 125:73-78.
20.07.2018Disturbed sphingolipid metabolism with elevated 1-deoxysphingolipids in glycogen storage disease type I - A link to metabolic control
20.07.2018Mol Genet Metab 2018; 125:73-78
Hornemann Thorsten, Baumgartner Matthias R, Christ Emanuel, Bilz Stefan, Meienberg Fabian, Jung Hans H, Gautschi Matthias, Cremonesi Alessio, Zhakupova Assem, Hagenbuch Niels, Alecu Irina, Hochuli Michel
Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis
Navarini A, Bignucolo O, Meyer B, Meienberg F, Mehling M, Jeker L, Heijnen I, Daikeler T, Gebbers J, Grimbacher B, Sansom D, Jeker R, Hess C, Jauch A, Kistner A, Bigler M, Hruz P, Berger C, Hou T, Schwab C, Gabrysch A, Higgins R, Frede N, Padberg S, Kämpe O, Burgener A, Marquardsen F, Baldin F, Recher M. Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis. J Allergy Clin Immunol 2016; 139:1043-1046.e5.
28.11.2016Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis
28.11.2016J Allergy Clin Immunol 2016; 139:1043-1046.e5
Navarini Alexander A, Bignucolo Olivier, Meyer Benedikt, Meienberg Fabian, Mehling Matthias, Jeker Lukas T, Heijnen Ingmar, Daikeler Thomas D, Gebbers Jan-Olaf, Grimbacher Bodo, Sansom David M, Jeker Raphael, Hess Christoph, Jauch Annaise, Kistner Anne, Bigler Marc, Hruz Petr, Berger Christoph T, Hou Tie Zheng, Schwab Charlotte, Gabrysch Annemarie, Higgins Rebecca, Frede Natalie, Padberg Sgier, Kämpe Olle, Burgener Anne-Valérie, Marquardsen Florian, Baldin Fabian, Recher Mike
Concentrations of the stress hormone copeptin increase upon hypoglycaemia in patients with type 1 diabetes dependent of hypoglycaemia awareness
Seelig E, Bilz S, Keller U, Meienberg F, Christ-Crain M. Concentrations of the stress hormone copeptin increase upon hypoglycaemia in patients with type 1 diabetes dependent of hypoglycaemia awareness. PloS one 2013; 8:e72876.
30.08.2013Concentrations of the stress hormone copeptin increase upon hypoglycaemia in patients with type 1 diabetes dependent of hypoglycaemia awareness
30.08.2013PloS one 2013; 8:e72876
Seelig Eleonora, Bilz Stefan, Keller Ulrich, Meienberg Fabian, Christ-Crain Mirjam